MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyag322

Медицинская библиотека · The oncologist · 2026

Immunohistochemistry-based molecular subtypes and stromal tumor-infiltrating lymphocytes in triple-negative breast cancer: a chemotherapy-only cohort.

Hernandez-Hernandez Jesus Edgardo, Mohar Alejandro, Lara-Torres César Octavio, Vazquez-Juarez Daniela, Palacios Tamara, Peña-Torres Lourdes, Moncada-Claudio Guadalupe, Velazquez-Martinez Areli, Cabrera-Galeana Paula, Gómez-Macías Gabriela Sofía, Porras-Reyes Fany Iris, Pérez-Sánchez Víctor Manuel, Aranda-Gutierrez Alejandro, Villarreal-Garza Cynthia

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Triple-negative breast cancer (TNBC) is a biologically heterogeneous, aggressive disease where immunohistochemistry (IHC)-based algorithms, defining luminal androgen receptor (LAR), immunomodulatory (IM), basal-like immunosuppressed (BLIS), mesenchymal (MES), and unclassifiable (UC) subtypes, offer a pragmatic alternative to transcriptomics. This study evaluated clinical trajectories and survival outcomes associated with IHC-based molecular subtypes and stromal tumor-infiltrating lymphocytes (sTILs) across distinct subgroups.

METHODS

A retrospective analysis of 289 women with TNBC treated with chemotherapy-only regimens analyzed molecular subtypes across four clinical groups: non-recurrent, recurrent, progression during neoadjuvant chemotherapy, and de novo metastatic disease. IHC-based subclassification included androgen receptor (AR), CD8, FOXC1, and DCLK1 biomarkers. Overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method, and multivariable Cox proportional hazards models.

RESULTS

The cohort included non-recurrent (43.9%), recurrent (26.3%), neoadjuvant progressors (11.5%), and de novo stage IV (18.3%) cases. IM subtype (16.3%) was enriched in non-recurrent cases with the highest median sTILs levels (20.0%). BLIS (26.3%) and UC (39.4%) subtypes predominated in recurrent and metastatic disease, while MES subtype (9.0%) predominated in neoadjuvant chemotherapy progressors. In early-stage disease, sTILs ≥10% independently predicted superior OS (HR 0.63, 95% CI, 0.40-1.0; P = .049), showing no prognostic role in the de novo stage IV group. Molecular subtypes lost independent significance in multivariable models.

CONCLUSIONS

Clinicopathological factors and sTILs remain primary prognostic determinants in TNBC. Although IHC-based molecular subtypes were not independent survival predictors, their differential clinical distribution validates their biological relevance to identify therapeutic vulnerabilities, and to guide precision medicine and de-escalation strategies.

Для цитирования: Hernandez-Hernandez Jesus Edgardo, Mohar Alejandro, Lara-Torres César Octavio, Vazquez-Juarez Daniela, Palacios Tamara, Peña-Torres Lourdes, Moncada-Claudio Guadalupe, Velazquez-Martinez Areli, Cabrera-Galeana Paula, Gómez-Macías Gabriela Sofía, Porras-Reyes Fany Iris, Pérez-Sánchez Víctor Manuel, Aranda-Gutierrez Alejandro, Villarreal-Garza Cynthia. Immunohistochemistry-based molecular subtypes and stromal tumor-infiltrating lymphocytes in triple-negative breast cancer: a chemotherapy-only cohort.. The oncologist. 2026. DOI: 10.1093/oncolo/oyag322.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.